A 10% ready-to-use intravenous human immunoglobulin offers potential economic advantages over a lyophilized product in the treatment of primary immunodeficiency

Por Kallenberg, C G M
Publicado em 2007

Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: where to go?

Por Kallenberg, C G M
Publicado em 2011

Are anti-neutrophil cytoplasmic antibodies (ANCA) clinically useful in inflammatory bowel disease (IBD)?

Por Roozendaal, C, Kallenberg, C G M
Publicado em 1999

Anti-CD3-induced and anti-Fas-induced apoptosis in systemic lupus erythematosus (SLE)

Por Bijl, M, Horst, G, Limburg, P C, Kallenberg, C G M
Publicado em 2001

Bosentan therapy for patients with severe Raynaud's phenomenon in systemic sclerosis

Por Hettema, M E, Zhang, D, Bootsma, H, Kallenberg, C G M
Publicado em 2007

B cell epitope specificity in ANCA-associated vasculitis: does it matter?

Por VAN DER GELD, Y M, STEGEMAN, C A, KALLENBERG, C G M
Publicado em 2004

Characterization of monoclonal antibodies to proteinase 3 (PR3) as candidate tools for epitope mapping of human anti-PR3 autoantibodies

Por Van Der Geld, Y M, Limburg, P C, Kallenberg, C G M
Publicado em 1999

Reduced uptake of apoptotic cells by macrophages in systemic lupus erythematosus: correlates with decreased serum levels of complement

Por Bijl, M, Reefman, E, Horst, G, Limburg, P C, Kallenberg, C G M
Publicado em 2006

Plasma levels of soluble interleukin 2 receptor, soluble CD30, interleukin 10 and B cell activator of the tumour necrosis factor family during follow‐up in vasculitis associated wi...

Por Sanders, J‐S F, Huitma, M G, Kallenberg, C G M, Stegeman, C A
Publicado em 2006

Staphylococcal superantigens and T cell expansions in Wegener's granulomatosis

Por POPA, E R, STEGEMAN, C A, BOS, N A, KALLENBERG, C G M, TERVAERT, J W Cohen
Publicado em 2003

Are circulating neutrophils intravascularly activated in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides?

Por MULLER KOBOLD, A C, MESANDER, G, STEGEMAN, C A, KALLENBERG, C G M, COHEN TERVAERT, J W
Publicado em 1998

Anti-dsDNA production coincides with concurrent B and T cell activation during development of active disease in systemic lupus erythematosus (SLE)

Por SPRONK, P E, HORST, G, VAN DER GUN, B T F, LIMBURG, P C, KALLENBERG, C G M
Publicado em 1996

Skin Autofluorescence, as Marker of Accumulation of Advanced Glycation Endproducts and of Cumulative Metabolic Stress, Is Not Increased in Patients with Systemic Sclerosis

Por Hettema, M. E., Bootsma, H., Graaff, R., de Vries, R., Kallenberg, C. G. M., Smit, A. J.
Publicado em 2011

Progression of salivary gland dysfunction in patients with Sjögren's syndrome

Por Pijpe, J, Kalk, W W I, Bootsma, H, Spijkervet, F K L, Kallenberg, C G M, Vissink, A
Publicado em 2007

Inhibition of neutrophil-mediated production of reactive oxygen species (ROS) by endothelial cells is not impaired in anti-neutrophil cytoplasmic autoantibodies (ANCA)-associated v...

Por Al Laham, F, Kälsch, A-I, Heinrich, L, Birck, R, Kallenberg, C G M, Heeringa, P, Yard, B
Publicado em 2010

Levels of soluble FcγRIII correlate with disease severity in sepsis

Por Muller Kobold, A C, Zijlstra, J G, Koene, H R, DE Haas, M, Kallenberg, C G M, Cohen Tervaert, J W
Publicado em 1998

Recombinant proteinase 3 (Wegener's antigen) expressed in Pichia pastoris is functionally active and is recognized by patient sera

Por HARMSEN, M C, HEERINGA, P, VAN DER GELD, Y M, HUITEMA, M G, KLIMP, A, TIRAN, A, KALLENBERG, C G M
Publicado em 1997

Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease

Por Holvast, A, Huckriede, A, Wilschut, J, Horst, G, De Vries, J J C, Benne, C A, Kallenberg, C G M, Bijl, M
Publicado em 2006

In vitro T lymphocyte responses to proteinase 3 (PR3) and linear peptides of PR3 in patients with Wegener's granulomatosis (WG)

Por Van Der Geld, Y M, Huitema, M G, Franssen, C F M, Van Der Zee, R, Limburg, P C, Kallenberg, C G M
Publicado em 2000

Catalase and α-enolase: two novel granulocyte autoantigens in inflammatory bowel disease (IBD)

Por Roozendaal, C, Zhao, M H, Horst, G, Lockwood, C M, Kleibeuker, J H, Limburg, P C, Nelis, G F, Kallenberg, C G M
Publicado em 1998